author-photo

Stina Söderlund

Uppsala University Hospital

28

Papers

766

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

2020 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (2)
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

2019 OncoImmunology
Show All
- Source
- Cite
- Save
Citations (11)
Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis

2019 EBioMedicine
Show All
- Source
- Cite
- Save
Citations (0)
Single-cell analysis reveals the KIT D816V mutation in hematopoietic stem and progenitor cells in systemic mastocytosis: Supplementary data

2018
Show All
- Source
- Cite
- Save
Citations (0)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (262)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

2017 Leukemia
Show All
- Source
- Cite
- Save
Citations (133)
Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

2016 Haematologica
Show All
- Source
- Cite
- Save
Citations (0)
In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia

2016 Therapeutic Drug Monitoring
Show All
- Source
- Cite
- Save
Citations (9)